Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 5398-020-27	SERIAL NO. 10/053,975
		APPLICANT Limin LI, et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE January 18, 2002	GROUP ART UNIT 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
BF	AA	5,891,668	04/06/99	LI, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
BF	AK	WO 97/18333	05/22/97	WIPO	X	
	AL					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

BF	AP	Hoffman, et al., "Noncanonical *MMS2*-Encoded Ubiquitin-Conjugating Enzyme Functions in Assembly of Novel Polyubiquitin Chains for DNA Repair", Cell, Vol. 96, No. 5, pp. 645-653, 1999.
	AQ	Li, et al., "The *TSG101* Tumor Susceptibility Gene Is Located in Chromosome 11 Band p15 and Is Mutated in Human Breast Cancer", Cell, Vol. 88, No. 1, pp. 143-154, 1997.
	AR	Sancho, et al., "Role of UEV-1, an Inactive Variant of the E2 Ubiquitin-Conjugating Enzymes, in In Vitro Differentiation and Cell Cycle Behavior of HT-29-M6 Intestinal Mucosecretory Cells", Molecular and Cellular Biology, Vol. 8, No. 1, pp. 576-589, 1998.
	AS	Li, et al., "A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control", Proc. Natl. Acad. Sci. USA, Vol. 98, No. 4, pp. 1619-1624, 2001.
BF	AT	Pornillos, et al., "Structure and functional interactions of Tsg101 UEV domain", EMBO Journal, Vol. 21, No. 10, pp. 2397-2406, 2002.

EXAMINER	DATE CONSIDERED
Brandon Ratte	1/21/05

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/053,975
Filing Date	January 18, 2002
First Named Inventor	LI, LIMIN
Art Unit	1653
Examiner Name	
Attorney Docket Number	STAN-216

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BF		5,891,668	04-06-1999	LI et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]–Number[4]–Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[7]

Examiner Signature	Brenda Brumback	Date Considered	1/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Please type a plus sign (+) inside this box → [+]

JUN 17 2002

PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/053,975
				Filing Date	January 18, 2002
				First Named Inventor	Li, et al.
(use as many sheets as necessary)				Group Art Unit	Unassigned
Sheet	1	of	4	Examiner Name	Unassigned
				Attorney Docket Number	STAN-216

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Documents Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Documents Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

[+]

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
BF	1	BAKER, et al. *"Suppression of human colorectal carcinoma cell growth by wild-type p53"*, Science Vol. 249: 912-915 (1990).	
	2	BUSCHMANN, et al. *"SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53"*, Cell Vol. 101: 753-762 (2000).	
	3	CHEN, et al. *"Mapping of the p53 and mdm-2 interaction domains"*, Molecular and Cellular Biology Vol. 13(7): 4107-4114 (1993).	
	4	FANG, et al. *"Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53"*, J. Biol. Chem. Vol. 275(12): 8945-8951 (2000).	
	5	FENG, et al. *"TSG101 protein steady-state level is regulated posttranslationally by an evolutionarily conserved COOH-terminal sequence"*, Cancer Research Vol. 60: 1736-1741 (2000).	
	6	FIDDLER, et al. *"Amplification of MDM2 inhibits MyoD-mediated myogenesis"*, Molecular and Cellular Biology Vol. 16(9): 5048-5057 (1996).	
	7	FREEDMAN, et al. *"Regulation of the p53 protein by the MDM2 oncoprotein – Thirty-eight G.H.A. Clowes memorial award lecture"*, Cancer Research Vol. 59: 1-7 (1999).	
BF	8	GAYTHER, et al. *"Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours"*, Oncogene Vol. 15: 2119-2126 (1997).	

Examiner Signature	Brandon Fortner	Date Considered	1/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/053,975
Filing Date	January 18, 2002
First Named Inventor	Li, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	STAN-216

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
BF		HAUPT, et al. *"Mdm2 promotes the rapid degradation of p53"*, Nature Vol. 387: 296-299 (1997).	
		HITTLELMANN, et al. *"Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins"*, The EMBO J. Vol. 18(19): 5380-5388 (1999).	
		HOCHSTRASSER. *"All in the ubiquitin family"*, Science Vol. 289: 563-564 (2000).	
		HONDA, et al. *"Association of $p19^{ARF}$ with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53"*, The EMBO J. Vol. 18(1): 22-27 (1999).	
		HSIEH, et al. *"RB regulates the stability and the apoptotic function of p53 via MDM2"*, Mol. Cell Vol. 3: 181-193 (1999).	
		JONES, et al. *"Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53"*, Nature Vol. 378: 206-208 (1995).	
		KOONIN, et al. *"TSG101 may be the prototype of a class of dominant negative ubiquitin regulators"*, Nature Genetics Vol. 16: 330-331 (1997).	
		KUBBUAT, et al. *"Regulation of p53 stability by Mdm2"*, Nature Vol. 387: 299-303 (1997).	
		LANE, et al. *"MDM2 – arbiter of p53's destruction"*, Trends Biochem. Sci. Vol. 22: 372-374 (1997).	
		LEE, et al. *"Aberrant splicing but not mutations of TSG101 in human breast cancer"*, Cancer Research, Vol. 57: 3131-3134 (1997).	
		LEVINE, et al. *"The spectrum of mutations at the p53 locus: Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype"*, Ann. NY Acad. Sci. Vol. 768: 111-128 (1995).	
		LEVINE. *"p53, the cellular gatekeeper for growth and division"*, Cell Vol. 88: 323-331 (1997).	
		LI, et al. *"tsg101: A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells"*, Cell Vol. 85: 319-329 (1996).	
BF		MCMASTERS, et al. *"mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts"*, Oncogene Vol. 13: 1731-1736 (1996).	

Examiner Signature	Brandon Fetterolf	Date Considered	1/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/053,975
Filing Date	January 18, 2002
First Named Inventor	Li, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	STAN-216

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
SF		MONTES DE OCA LUNA, et al. *"Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53"*, Nature Vol. 378: 203-206 (1995).	
		OLSON, et al. *"Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes"* Oncogene Vol. 8: 2353-2360 (1993).	
		OREN. *"Regulation of the p53 tumor suppressor protein"*, J. Biol. Chem. Vol. 274(51): 36031-36034 (1999).	
		PONTING, et al. *"The breast cancer gene product TSG101: A regulator of ubiquitination?"*, J. Mol. Med. Vol. 75: 467-469 (1997).	
		PRIVES. *"The MDM2-p53 circuit"*, Cell Vol. 95: 5-8 (1998).	
		ROTH, et al. *"Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein"*, The EMBO J. Vol. 17(2): 554-564 (1998).	
		RULAND, et al. *"p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101"*, PNAS Vol. 98(4): 1859-1864 (2001).	
		SHERR, et al. *"The ARF/p53 pathway"*, Curr. Opin. Genet. Dev. Vol. 10: 94-99 (2000).	
		SUN, et al. *"Frequent abnormalities of TSG101 transcripts in human prostate cancer"*, Oncogene Vol. 15: 3121-3125 (1997).	
		SUN, et al. *"Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300"*, Cancer Vol. 86: 689-696 (1999).	
		TURPIN, et al. *"Stress-induced aberrant splicing of TSG101: Association to high tumor grade and p53 status in breast cancers"*, Oncogene Vol. 18: 7834-7837 (1999).	
		VANDEMARK, et al. *"Molecular insights into polyubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer"*, Cell Vol. 105: 711-720 (2001).	
		VOUSDEN, et al. *"p53: Death Star"*, Cell Vol. 103: 691-694 (2002).	
		WAGNER, et al. *"Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: Common types of shorter transcripts are true alternative splice variants"*, Oncogene Vol. 17: 2761-2770 (1998).	
SF		WARD, et al. *"Degradation of CFTR by the ubiquitin-proteasome pathway"*, Cell Vol. 83: 121-127 (1995).	

Examiner Signature		Date Considered	1/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/053,975
				Filing Date	January 18, 2002
				First Named Inventor	Li, et al.
(use as many sheets as necessary)				Group Art Unit	Unassigned
Sheet	4	of	4	Examiner Name	Unassigned
				Attorney Docket Number	STAN-216

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		WATANABE, et al. *"A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled –coil domain"*, Biochem. Biophys. Res. Commun. Vol. 245: 900-905 (1998).	
		WEISSMAN. *"Themes and variations on ubiquitylation"*, Nature Reviews Vol. 2:169-178 (2001).	
		XIE, et al. *"Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency"*, Proc. Natl. Acad. Sci. USA Vol. 95: 1595-1600 (1998).	
		ZHANG, et al. *"ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways"*, Cell Vol. 92: 725-734 (1998).	

Examiner Signature		Date Considered	1/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.